Contributors: Turku University Hospital (TYKS); Department of Epidemiology and Public Health; University College of London London (UCL); Unit of Excellence for Psychosocial Factors; Finnish Institute of Occupational Health; 1st Department of Medicine; Semmelweis University of Medicine Budapest; MRC Centre for Causal Analyses in Translational Epidemiology; University of Bristol Bristol; MRC/CSO Social and Public Health Sciences Unit Glasgow, UK; Institute of Health and Wellbeing; College of Medical, Veterinary and Life Sciences Glasgow; University of Glasgow-University of Glasgow-College of Medical, Veterinary and Life Sciences Glasgow; University of Glasgow-University of Glasgow; Centre for Cognitive Ageing and Cognitive Epidemiology; University of Edinburgh (Edin.); Santé publique et épidémiologie des déterminants professionnels et sociaux de la santé; Epidémiologie, sciences sociales, santé publique (IFR 69); Université Paris 1 Panthéon-Sorbonne (UP1)-Université Paris-Sud - Paris 11 (UP11)-École des hautes études en sciences sociales (EHESS)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris 1 Panthéon-Sorbonne (UP1)-Université Paris-Sud - Paris 11 (UP11)-École des hautes études en sciences sociales (EHESS)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut National de la Santé et de la Recherche Médicale (INSERM); Department of Psychology; Steno Diabetes Center; University of Copenhagen = Københavns Universitet (UCPH); MK and JV are supported by the Academy of Finland. MK is additionally supported by a BUPA Foundation Specialist Research Grant, UK, the National Heart, Lung, and Blood Institute (R01HL036310) and the National Institute on Aging (R01AG034454)/NIH, USA; GDB is a Wellcome Trust Research Fellow, UK; AS-M is supported by a ‘EURYI' award from the European Science Foundation; and DAL works in a centre that receives some core funding from the UK Medical Research Council (MRC). The MRC Social and Public Health Sciences Unit receives funding from the UK MRC and the Chief Scientist Office at the Scottish Government Health Directorates. The Centre for Cognitive Ageing and Cognitive Epidemiology is supported by the Biotechnology and Biological Sciences Research Council, the Engineering and Physical Sciences Research Council, the Economic and Social Research Council, the Medical Research Council, and the University of Edinburgh as part of the cross-council Lifelong Health and Wellbeing initiative.
نبذة مختصرة : International audience ; OBJECTIVE: To examine antidepressant use before and after the diagnosis of diabetes. RESEARCH DESIGN AND METHODS: This study was a longitudinal analysis of diabetic and nondiabetic groups selected from a prospective cohort study of 151,618 men and women in Finland (the Finnish Public Sector Study, 1995-2005). We analyzed the use of antidepressants in those 493 individuals who developed type 2 diabetes and their 2,450 matched nondiabetic control subjects for each year during a period covering 4 years before and 4 years after the diagnosis. For comparison, we undertook a corresponding analysis on 748 individuals who developed cancer and their 3,730 matched control subjects. RESULTS: In multilevel longitudinal models, the odds ratio for antidepressant use in those who developed diabetes was 2.00 (95% CI 1.57-2.55) times greater than that in nondiabetic subjects. The relative difference in antidepressant use between these groups was similar before and after the diabetes diagnosis except for a temporary peak in antidepressant use at the year of the diagnosis (OR 2.66 [95% CI 1.94-3.65]). In incident cancer case subjects, antidepressant use substantially increased after the cancer diagnosis, demonstrating that our analysis was sensitive for detecting long-term changes in antidepressant trajectories when they existed. CONCLUSIONS: Awareness of the diagnosis of type 2 diabetes may temporarily increase the risk of depressive symptoms. Further research is needed to determine whether more prevalent use of antidepressants noted before the diagnosis of diabetes relates to effects of depression, side effects of antidepressant use, or a common causal pathway for depression and diabetes.
_1.png)
Processing Request
No Comments.